Related Experiment Video
Updated: May 25, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
Is the pneumococcal vaccine Advance Market Commitment motivating innovation and increasing manufacturing capacity?
1Plahte Research & Consulting, Bølerveien 12e, N-0690 Oslo, Norway. jens@plahte.info
Abstract:
This paper seeks to give some preliminary evidence on the potential outcome of the pneumococcal vaccine Advance Market Commitment (AMC), with a focus on its impact on innovation in 'emerging' vaccine manufacturers in developing countries. The evidence is derived from a series of interviews with executives at industrial vaccine developing organizations with pneumococcal vaccines in their R&D portfolio, including both multinational pharmaceutical companies and 'emerging' manufacturers. The main findings are that so far there is no evidence to support any claim that the AMC is speeding innovation of pneumococcal vaccines, or that it is contributing to productive capacity expansion. Representatives of emerging manufacturers consistently state that the AMC is either irrelevant or inappropriate for supporting their innovative activities on pneumococcal vaccines.
Related Concept Videos
Vaccine Production
Microorganisms in Medicine and Therapeutics
Vaccinations
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

